Breaking News, Collaborations & Alliances

Accro Bioscience Grants Fosun Pharma Exclusive Rights for TYK2/JAK1 Inhibitor in Greater China

AC-201 is being developed to treat multiple immune-mediated inflammatory diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Accro Bioscience, a biotechnology company, has entered into an agreement granting Fosun Pharma exclusive rights to develop, manufacture, and commercialize its TYK2/JAK1 inhibitor, AC-201, in Greater China, encompassing Chinese Mainland, Hong Kong SAR, and Macau SAR. Accro will retain global rights for AC-201 outside these regions. Under the terms of the deal, Accro will receive an upfront payment of RMB 60 million and a milestone payment of RMB 20 million upon completion of manufacturing tech...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters